OC
CLDX icon

Oppenheimer & Co’s Celldex Therapeutics CLDX Stock Holding History

Oppenheimer & Co’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,116
Closed -$3K – 1354
2018
Q4 		$3K Sell
1,116
-400
-26% -$1.96K ﹤0.01% 1236
2018
Q3 		$11K Sell
1,516
-880
-37% -$6.16K ﹤0.01% 1342
2018
Q2 		$19K Sell
2,396
-1,955
-45% -$26.1K ﹤0.01% 1319
2018
Q1 		$152K Sell
4,351
-40
-0.9% -$1.55K ﹤0.01% 1257
2017
Q4 		$188K Buy
4,391
+391
+10% +$16.7K ﹤0.01% 1219
2017
Q3 		$172K Sell
4,000
-2,396
-37% -$89.8K ﹤0.01% 1198
2017
Q2 		$237K Sell
6,396
-329
-5% -$14.6K 0.01% 1111
2017
Q1 		$364K Sell
6,725
-1,114
-14% -$58K 0.01% 924
2016
Q4 		$417K Sell
7,839
-1,300
-14% -$74K 0.01% 871
2016
Q3 		$554K Sell
9,139
-2,085
-19% -$130K 0.02% 771
2016
Q2 		$739K Sell
11,224
-2,139
-16% -$136K 0.02% 644
2016
Q1 		$758K Sell
13,363
-374
-3% -$42.1K 0.02% 616
2015
Q4 		$3.23M Buy
13,737
+2,013
+17% +$439K 0.1% 243
2015
Q3 		$1.85M Buy
11,724
+275
+2% +$77.8K 0.06% 385
2015
Q2 		$4.33M Sell
11,449
-916
-7% -$364K 0.12% 198
2015
Q1 		$5.17M Sell
12,365
-1,492
-11% -$534K 0.14% 171
2014
Q4 		$3.79M Sell
13,857
-2,902
-17% -$721K 0.11% 222
2014
Q3 		$3.26M Buy
16,759
+1,225
+8% +$267K 0.1% 250
2014
Q2 		$3.8M Buy
15,534
+3,002
+24% +$678K 0.11% 212
2014
Q1 		$3.32M Buy
12,532
+5,377
+75% +$2.06M 0.1% 247
2013
Q4 		$2.6M Sell
7,155
-50
-0.7% -$19.3K 0.08% 295
2013
Q3 		$3.83M Sell
7,205
-727
-9% -$249K 0.13% 195
2013
Q2 		$1.86M Buy
+7,932
New +$1.56M 0.07% 321

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Oppenheimer & Co's CLDX Position: Q1 2019 in Review

Oppenheimer & Co sold out of Celldex Therapeutics (CLDX) in Q1 2019, closing a stake of 1,116 shares — an estimated $3K sold.

Oppenheimer & Co first reported a position in CLDX in Q2 2013 and held it in 23 quarters. The position peaked at $5.17M in Q1 2015. 53 funds tracked by Wall St. Rank hold CLDX as of Q1 2019.

  • Oppenheimer & Co reported no remaining Celldex Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Oppenheimer & Co sold 1,116 Celldex Therapeutics shares in Q1 2019, an estimated $3K.
  • Oppenheimer & Co first reported a position in Celldex Therapeutics in Q2 2013 and held it in 23 quarters.
  • Oppenheimer & Co's Celldex Therapeutics position peaked at $5.17M in Q1 2015.
  • 53 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2019.

Based on Oppenheimer & Co's 13F filing for Q1 2019, filed 24 Apr 2019.